1 unchanged sentence
(c) Trading Plans
−Removed: On January 30, 2026 , Dinesh V.
−Removed: Patel , Ph.D., our Chief Executive Officer and a member of our Board of Directors (the “Board”), adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 300,000 shares of the Company’s common stock through October 9, 2026 , or such earlier date when all transactions under the trading plan are completed, subject to certain conditions.
−Removed: On February 27, 2026 , William Waddill , a member of our Board , adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 27,000 shares of the Company’s common stock through May 31, 2027 , or such earlier date when all transactions under the trading plan are completed, subject to certain conditions.
−Removed: Except as discussed above, during the fiscal quarter ended March 31, 2026, no director or Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (in each case as defined in Item 408(a) of Regulation S-K).
+Added: On June 30, 2026 , Asif Ali , our Chief Financial Officer , adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to (i) 73,214 shares of the Company’s common stock, (ii) 50% of the net shares issued to Mr.
+Added: Ali after withholding taxes upon the vesting of restricted stock unit awards representing 21,346 shares of the Company’s common stock, and (iii) 50% of the net shares issued to Mr.
+Added: Ali after withholding taxes upon the vesting of performance stock unit awards representing 12,800 shares of the Company’s common stock (assuming that such shares underlying performance stock units vest at target amounts) through September 30, 2027 , or such earlier date when all transactions under the trading plan are completed, subject to certain conditions.
+Added: Except as discussed above, during the fiscal quarter ended June 30, 2026, no director or Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (in each case as defined in Item 408(a) of Regulation S-K).
EXHIBIT INDEX
4 unchanged sentences
Amended and Restated Bylaws
−Removed: Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Protagonist Therapeutics, Inc.
+Added: 2026 Equity Incentive Plan
+Added: Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities
+Added: Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
13 unchanged sentences
PROTAGONIST THERAPEUTICS, INC.
+Added: August 5, 2026
/s/ Dinesh V.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 5, 2026
Executive Vice President, Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.